I wonder if that’s just a paid ad 
What do you think?
2 Likes
At least I don’t have any greater wisdom on this. And my expertise isn’t enough to assess it. Quite a sensible thought.
2 Likes
In my opinion… after reading the whole thing, it’s the same as what others, like CVS, are doing. Efficiency must be increased, and what could be easier than AI screening? CVS, as I understand it, had those China junk products that will never get FDA approval. At some point, they’ll end up in the trash…
Pharmacies (too) are becoming very active in this area… This AEYE X Ford Medical case has been remarkably quiet, and they’ve been working on it for almost a year. I wonder if some information/customers will be coming soon, now that the Epic Case is also in order, and information + reimbursements move quickly through it. Aeye Health Ford Medical Partnership | Retinal Physician
1 Like
What does “China-made things” mean in this context? CVS Health is a US-based, publicly traded diversified healthcare company.
I don’t know if the equipment has been updated..
CVS Health offers teleretina exams at all of the more than 1,200 MinuteClinic locations using the Welch Allyn RetinaVue 700 Imager and an off-site ophthalmologist.
One can’t know for sure, but I don’t really believe that CVS would now extensively invest in a solution that is not approved for autonomous diagnostics and directly burdens ophthalmologists, without improving efficiency. A lot of time has passed since then. On the other hand, there are no guarantees that they would specifically use Optomed’s solution either. However, I don’t believe that the Welch Allyn RetinaVue 700 Imager will be in use there. Regarding the 2023 program, I recall it being mentioned here earlier that it has been discontinued.
“Editor’s note: This article was updated October 5, 2023, to reflect that in August 2023, MinuteClinic had discontinued its retinal screening program.”
Optomed is still quite expensive if it doesn’t start making a decent profit. Even market leader Zeiss is valued at P/S 1. And Optomed is not an AI company; it’s a device manufacturer. Portability doesn’t seem to offer an advantage worth paying a premium for. And a smaller device loses out in usability, features, and image quality.
The number of diabetics continues to grow, but diabetes treatment is developing so nicely (sensors and smart pumps) that the need for retinopathy screening will likely decrease in the future, so roughly, the TAM (Total Addressable Market) will be flat in the future.
2 Likes